Detail akcie Bristol Myers online

Business Summary: Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Bristol-Myers Squibb Co revenues increased 7% to $24.07B. Net loss totaled $10.23B vs. income of $4.34B. Revenues reflect Eliquis segment increase of 8% to $7.14B, Reblozyl segment increase of 77% to $779M, United States segment increase of 8% to $17.28B, International segment increase of 2% to $6.41B. Net loss reflects Acquired IPRD increase from $233M to $13.08B (expense).